Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   
Assessing the Impact of Childhood Interventions on Subsequent Drug Use Home
Assessing the Impact of Childhood Interventions
on Subsequent Drug Use
skip navigation About the Conference
Agenda
Commissioned Papers
Barbara J. Burns, Ph.D.
Scott N. Compton, Ph.D.
Helen L. Egger, M.D.
Elizabeth M.Z. Farmer, Ph.D.
E. Jane Costello
Tonya D. Armstrong
Alaattin Erkanli
Paul E. Greenbaum
Chi-Ming Kam
Linda M. Collins
Selected Bibliography
Program Contacts

Report on the Developmental Epidemiology of Comorbid Psychiatric and Substance Use Disorders

Costello, Armstrong & Erkanli

Links to other parts of this paper:


Tables

Table 1. Rates of substance use and psychiatric comorbidity in community-based samples

Study

N

Age

Time frame

Pop rate of a (%)

Pop rate of b (%)

Rate of a in b(%)

Rate of a in not b (%)

Rate of b in a (%)

Rate of b in not a (%)

OR

CI

a=substance use, b=depression, in females

2

1265

12 to 16

6 mo

9.3

13.6

       

2.67

 

3

698

12 to 21

lifetime

27

0

       

1.3

1.0, 1.6

9

875

14 to 15

lifetime

9.8

         

n/a

 

10

464

15

lifetime

21.6

9.1

       

2.98

n/a

11

604

9 to 18

6 mo

41.7

7.2

   

25

5.3

5.8

4.2, 6.4

17

2346

12 to 17

1 mo

n/a

14.5

16.6

6.4

   

2.8

2.3, 3.3

19

548

16 to 17

6 mo

8.4

         

n/a

 

21

561

15 to 16

1 mo

11.5

18.9

4.3

     

0.3

0.1, 0.5

a=substance use, b=depression, in males

2

1265

12 to 16

6 mo

6.9

4.9

       

2.67

 

3

698

12 to 21

lifetime

27

         

1.3

1.0, 1.6

9

875

14 to 15

lifetime

9.8

         

n/a

 

10

492

15

lifetime

19.1

7.3

       

1.38

 

11

681

9 to 18

6 mo

41.7

7.2

   

23.3

4.8

6

4.3, 7.7

17

2352

12 to 17

1 mo

 

13.8

13.9

7.6

   

1.9

1.5, 2.3

19

519

16 to 17

6 mo

16.6

         

n/a

 

21

533

15 to 16

1 mo

25.6

9.9

5.8

     

0.2

0.1, 0.3

a=substance use, b=anxiety, in females

2

1265

12 to 16

6 mo

9.3

13.6

       

2.67

n/a

3

698

12 to 21

lifetime

27

         

1.3

1.0, 1.6

9

875

14 to 15

lifetime

9.8

         

n/a

 

10

464

15

lifetime

21.6

         

n/a

 

11

604

9 to 18

6 mo

41.7

13

   

33.3

11.4

6.7

5.3, 8.1

17

2346

12 to 17

1 mo

 

14.5

16.6

6.4

   

2.9

2.4, 3.4

19

548

16 to 17

6 mo

8.4

         

n/a

n/a

21

561

15 to 16

1 mo

11.5

         

n/a

 
a=substance use, b=anxiety, in males

2

1265

12 to 16

6 mo

6.9

4.9

       

2.7

n/a

3

698

12 to 21

lifetime

27

         

1.3

1.0, 1,6

9

875

14 to 15

lifetime

9.8

         

n/a

 

10

492

15

lifetime

19.1

         

n/a

 

11

681

9 to 18

6 mo

41.7

13

   

16.7

11.7

2.2

1.6, 2.8

17

2352

12 to 17

1 mo

 

13.8

13.9

7.6

   

1.9

1.5, 2.3

19

519

16 to 17

6 mo

16.6

         

n/a

 

21

533

15 to 16

1 mo

25.6

         

n/a

 
a=substance use, b=ADHD, in females

2

1265

12 to 16

6 mo

9.3

3.3

       

0.6

n/a

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.6

20

     

0.7

0.5, 0.9

10

464

15

lifetime

21.6

         

n/a

 

11

604

9 to 18

6 mo

41.7

10.3

   

33.3

5.6

8.3

6.1, 10.5

17

2346

12 to 17

1 mo

 

21.7

21.1

4.2

   

6.8

5.7, 7.9

19

548

16 to 17

6 mo

8.4

6.4

18.8

7.4

   

2.9

1.5, 4.3

21

561

15 to 16

1 mo

11.5

         

n/a

 
a=substance use, b=ADHD, in males

2

1265

12 to 16

6 mo

6.9

7.3

       

0.6

n/a

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.6

20

     

0.7

0.5, 0.9

10

492

15

lifetime

19.1

         

n/a

 

11

681

9 to 18

6 mo

41.7

10.3

   

50

9.3

9.8

7.8, 11.8

17

2352

12 to 17

1 mo

 

15.8

21.4

6.1

   

4.2

3.8, 5.6

19

519

16 to 17

6 mo

16.6

6.4

10.7

13.4

   

0.8

0.5, 1.3

21

533

15 to 16

1 mo

25.6

         

n/a

 
a=substance use, b=ODD, in females

2

1265

12 to 16

6 mo

9.3

         

n/a

 

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.1

21.13

     

2.8

1.9, 3.7

10

464

15

lifetime

21.6

         

n/a

 

11

604

9 to 18

6 mo

41.7

10.3

   

33.3

5.6

8.3

6.1, 10.5

17

2346

12 to 17

1 mo

 

21.7

21.1

4.2

   

6.1

5.1, 7.1

19

548

16 to 17

6 mo

8.4

5

26.7

7.4

   

4.6

2.5, 6.7

21

561

15 to 16

1 mo

11.5

         

n/a

   
a=substance use, b=ODD, in males

2

1265

12 to 16

6 mo

6.9

         

n/a

 

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.1

21.13

     

2.8

1.9, 3.7

10

492

15

lifetime

19.1

         

n/a

 

11

681

9 to 18

6 mo

41.7

10.3

   

50

9.3

9.8

7.7, 11.9

17

2352

12 to 17

1 mo

 

15.8

21.4

6.1

   

4.2

3.6, 4.8

19

519

16 to 17

6 mo

16.6

5

30

13.4

     

2.8

1.6, 4.0

21

533

15 to 16

1 mo

25.6

         

n/a

 
a=substance use, b=CD, in females

2

1265

12 to 16

6 mo

9.3

4

       

20.3

n/a

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.1

21.13

     

2.8

1.9, 3.7

10

464

15

lifetime

21.6

10.3

       

10.35

n/a

11

604

9 to 18

6 mo

41.7

10.3

   

33.3

5.6

8.3

6.1, 10.5

17

2346

12 to 17

1 mo

 

21.7

21.1

4.2

   

6.1

5.1, 7.1

19

548

16 to 17

6 mo

8.4

5

26.7

7.4

   

4.6

2.5, 6.7

21

561

15 to 16

1 mo

11.5

         

n/a

 
a=substance use, b=CD, in males

2

1265

12 to 16

6 mo

6.9

10.4

       

3.28

n/a

3

698

12 to 21

lifetime

27

         

n/a

 

9

875

14 to 15

lifetime

9.8

8.1

21.13

     

2.8

1.9, 3.7

10

492

15

lifetime

19.1

6.9

       

12.69

n/a

11

681

9 to 18

6 mo

41.9

10.3

   

50

9.3

9.8

7.8, 11.8

17

2352

12 to 17

1 mo

 

15.8

21.4

6.1

   

4.2

3.6, 4.8

19

519

16 to 17

6 mo

16.6

5

30

13.4

   

2.8

1.6, 4.0

21

533

15 to 16

1 mo

25.6

         

n/a

 

Note.

Study 2. Boyle & Offord, 1991
Study 3. Brook, Cohen, & Brook, 1998
Study 9. Fergusson, Lynskey, & Horwood, 1993
Study 10. Henry, Feehan, McGee, Stanton, Moffitt, & Silva, 1993
Study 11. Kandel, Johnson, Bird, Canino, Goodman, Lahey, Regier, & Schwab-Stone, 1997
Study 17. Substance Abuse and Mental Health Services Administration, 1996
Study 19. Windle & Windle, 1993
Study 21. Windle & Davies, 1999
ADHD = attention-deficit/hyperactivity disorder; CD = conduct disorder; CI = confidence interval; ODD = oppositional defiant disorder; OR = odds ratio

Back to Top


Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal